Medifast (NYSE:MED) Announces Earnings Results, Beats Estimates By $0.36 EPS

Key Points

• Medifast beat estimates: Reported EPS of -$0.19 beat the consensus by $0.36, with revenue of $76.04 million versus the $69.20 million estimate.
• Weak forward guidance and stock reaction: The company updated FY2026 guidance to -2.75 to -1.55 EPS and Q2 2026 to -1.00 to -0.50, and the shares traded down about 3% to $10.58.
• Insider buy vs. analyst sentiment: CEO Daniel R. Chard purchased 17,678 shares at ~$10.11, while analysts' consensus rating remains a "Reduce" with a $12 target.

Medifast (NYSE:MED - Get Free Report) announced its earnings results on Monday. The specialty retailer reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.36, FiscalAI reports. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The company had revenue of $76.04 million during the quarter, compared to the consensus estimate of $69.20 million. Medifast updated its FY 2026 guidance to -2.750--1.550 EPS and its Q2 2026 guidance to -1.000--0.500 EPS.

Medifast Trading Down 3.0%

Medifast stock traded down $0.33 on Monday, hitting $10.58. 149,536 shares of the stock traded hands, compared to its average volume of 241,665. Medifast has a 1 year low of $9.22 and a 1 year high of $15.46. The firm has a market cap of $116.76 million, a P/E ratio of -6.19 and a beta of 0.55. The business's fifty day simple moving average is $10.41 and its 200 day simple moving average is $11.10.

Analyst Ratings Changes

MED has been the subject of several research reports. Wall Street Zen upgraded shares of Medifast from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Medifast in a research note on Thursday, January 22nd. Finally, Stephens decreased their price target on shares of Medifast from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and a consensus target price of $12.00.

Insider Buying and Selling at Medifast

In other Medifast news, CEO Daniel R. Chard purchased 17,678 shares of the firm's stock in a transaction that occurred on Friday, March 20th. The stock was bought at an average cost of $10.11 per share, for a total transaction of $178,724.58. Following the purchase, the chief executive officer directly owned 17,678 shares in the company, valued at $178,724.58. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Medifast

Large investors have recently modified their holdings of the stock. Prudential Financial Inc. purchased a new position in shares of Medifast in the second quarter worth $200,000. Barclays PLC grew its holdings in Medifast by 10.6% during the fourth quarter. Barclays PLC now owns 16,769 shares of the specialty retailer's stock valued at $179,000 after purchasing an additional 1,608 shares during the period. Engineers Gate Manager LP bought a new stake in Medifast during the second quarter valued at about $161,000. Wells Fargo & Company MN grew its holdings in Medifast by 36.9% during the fourth quarter. Wells Fargo & Company MN now owns 14,169 shares of the specialty retailer's stock valued at $151,000 after purchasing an additional 3,821 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Medifast in the third quarter valued at about $144,000. Hedge funds and other institutional investors own 95.51% of the company's stock.

About Medifast

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.